E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

被引：41
|
作者：
Claudiani, Simone [1 ]
Apperley, Jane F. [1 ]
Gale, Robert Peter [1 ]
Clark, Richard [2 ]
Szydlo, Richard [1 ]
Deplano, Simona [1 ]
Palanicawandar, Renuka [1 ]
Khorashad, Jamshid [1 ]
Foroni, Letizia [1 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 08期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSE; YOUNG-ADULTS; IMATINIB; E13A2; TRIAL;
D O I：
10.3324/haematol.2017.168740
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E297 / E299
页数：3
相关论文
共 50 条
  • [41] In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants
    Soverini, Simona
    De Benedittis, Caterina
    Castagnetti, Fausto
    Gugliotta, Gabriele
    Mancini, Manuela
    Bavaro, Luana
    Polakova, Katerina Machova
    Linhartova, Jana
    Iurlo, Alessandra
    Russo, Domenico
    Pane, Fabrizio
    Saglio, Giuseppe
    Rosti, Gianantonio
    Cavo, Michele
    Baccarani, Michele
    Martinelli, Giovanni
    BMC CANCER, 2016, 16
  • [42] European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
    Mahon, Francois-Xavier
    Pfirrmann, Markus
    Dulucq, Stephanie
    Hochhaus, Andreas
    Panayiotidis, Panayiotis
    Almeida, Antonio
    Mayer, Jiri
    Hjorth-Hansen, Henrik
    Janssen, Jeroen J. W. M.
    Mustjoki, Satu
    Martinez-Lopez, Joaquin
    Vestergaard, Hanne
    Ehrencrona, Hans
    Polakova, Katerina Machova
    Olsson-Stroemberg, Ulla
    Ossenkoppele, Gert
    Berger, Marc G.
    Etienne, Gabriel
    Dengler, Jolanta
    Bruemmendorf, Tim H.
    Burchert, Andreas
    Rea, Delphine
    Rousselot, Philippe
    Nicolini, Franck E.
    Hofmann, Wolf-Karsten
    Richter, Johan
    Saussele, Susanne
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16) : 1875 - 1880
  • [43] BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors
    Song, Hye-young
    Noh, Hayeon
    Choi, Soo Young
    Lee, Sung-Eun
    Kim, Soo-Hyun
    Kee, Kyung-Mi
    Yoo, Hea-Lyun
    Lee, Mi-young
    Kang, Ki-Hoon
    Suh, Ji-Hyung
    Yang, Seon-young
    Jang, Eun-Jung
    Lee, Jangik, I
    Kim, Dong-Wook
    CANCER MEDICINE, 2018, 7 (10): : 5107 - 5117
  • [44] Long-Term Molecular Remission after Treatment with Imatinib in a Chronic Myeloid Leukemia Patient with Extreme Thrombocytosis Harboring Rare e14a3 (b3a3) BCR::ABL1 Transcript: A Case Report
    Zhang, Xupai
    Sun, Haoping
    Su, Yi
    Yi, Hai
    CURRENT ONCOLOGY, 2022, 29 (11) : 8171 - 8179
  • [45] Chronic myeloid leukemia with variant e19a2 BCR-ABL1 fusion transcript: interest of the molecular identification at diagnosis for minimal residual disease follow-up
    Gendron, Nicolas
    Belhouachi, Nabila
    Morel, Veronique
    Azgui, Zahia
    Maloum, Karim
    Florence Nguyen-Khac
    Cayuela, Jean-Michel
    Davi, Frederic
    Merle-Beral, Helene
    Chapiro, Elise
    ANNALES DE BIOLOGIE CLINIQUE, 2014, 72 (03) : 359 - 366
  • [46] Lymphoid blast crisis after prolonged treatment-free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de-escalation during the COVID-19 pandemic
    Avenoso, Daniele
    Milojkovic, Dragana
    Clark, James
    Pocock, Christopher
    Potter, Victoria
    Yallop, Deborah
    Hannah, Guy
    EJHAEM, 2022, 3 (01): : 215 - 217
  • [47] The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy
    Malcikova, Jitka
    Razga, Filip
    Jurcek, Tomas
    Dvorakova, Dana
    Zackova, Daniela
    Toskova, Martina
    Sebejova, Ludmila
    Smardova, Jana
    Oltova, Alexandra
    Vankova, Gabriela
    Jurackova, Lenka
    Trbusek, Martin
    Pospisilova, Sarka
    Mayer, Jiri
    Racil, Zdenek
    LEUKEMIA & LYMPHOMA, 2013, 54 (09) : 2083 - 2087
  • [48] A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD)
    Duan, M. -H.
    Li, H.
    Cai, H.
    LEUKEMIA RESEARCH, 2017, 59 : 8 - 11
  • [49] Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
    Branford, Susan
    Melo, Junia V.
    Hughes, Timothy P.
    BLOOD, 2009, 114 (27) : 5426 - 5435
  • [50] Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study
    Murbach, Bruna
    Duarte, Gislaine
    Palma, Leonardo Carvalho
    Miranda, Eliana
    Duffles, Guilherme
    Furlin, Graziele Pavan
    Toni, Isabella
    De Souza, Carmino
    Binelli, Larissa
    Bassan, Vitor Leonardo
    de Castro, Fabiola Attie
    Figueiredo-Pontes, Lorena Lobo de
    Pagnano, Katia Borgia Barbosa
    FRONTIERS IN ONCOLOGY, 2024, 14
12345